← Leaderboards
Limburg Paul
Mayo Clinic Rochester
$930,749
Attributed
$930,749
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $457.2K · FY2016–19$500K$375K$250K$125K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$930,749 · 1
By mechanism
N01$930,749 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Giles Richard Locke$2,467,349
- Meng Yin$9,336,704
- Yogesh Nellore Vilambi Reddy$503,231
Others in their field
Top investigators on “Standard Of Care”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Larry Arthur$176,170,000
- Philip J Disaia · University Of California Irvine$160,519,236
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$153,280,930
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$146,506,952
Research focus
Standard Of CareSignal TransductionAdverse EventAggressive FibromatosisAmerican Medical AssociationAnastomosis - ActionAnusClinical EfficacyClinical TrialsCohortDifferential ExpressionDoseDuodenal AdenomaAdverse EffectsEpidermal Growth Factor ReceptorErlotinibEsophagogastroduodenoscopyExanthemaAdenomatous Polyposis ColiFollow-UpGastrointestinal PolypGene ExpressionGenesTissues
Grant awards (4)
IGF::OT::IGF PHASE II TRIAL OF WEEKLY ERLOTINIB DOSING TO REDUCE DUADENAL POLYP BURDEN ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS$402,110
N01 · FY2019 · CA · contact PI
IGF::OT::IGF PHASE II TRIAL OF WEEKLY ERLOTINIB DOSING TO REDUCE DUADENAL POLYP BURDEN ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS$55,783
N01 · FY2018 · CA · contact PI
IGF::OT::IGF PHASE II TRIAL OF WEEKLY ERLOTINIB DOSING TO REDUCE DUADENAL POLYP BURDEN ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS$15,681
N01 · FY2017 · CA · contact PI
IGF::OT::IGF PHASE II TRIAL OF WEEKLY ERLOTINIB DOSING TO REDUCE DUADENAL POLYP BURDEN ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS$457,175
N01 · FY2016 · CA · contact PI